News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Call for funding for vision-saving drug

Media Release from the NZ Branch of the Royal Australian and New Zealand College of Ophthalmologists (RANZCO)


New Zealand Ophthalmologists call for funding for vision-saving drug

New Zealand Ophthalmologists (eye doctors) have repeated their call for government funding of a drug which treats the leading cause of blindness.

Ranibizumab (brand-name Lucentis®) can prevent vision loss from wet macular degeneration. It is funded in Australia, Canada, the US and Britain, but not in New Zealand, said Dr Iain Dunlop, President of the Royal Australian and New Zealand College of Ophthalmologists (RANZCO), in his address to the New Zealand Branch of RANZCO’s annual meeting in Christchurch.

Auckland Ophthalmologist, Dr Dianne Sharp, outlined a compelling health economic case for government funding of Lucentis®.

“Neovascular macular degeneration affects 15,000 New Zealanders and is the leading cause of blindness,” Dr Sharp explained. “Previous treatments have only been able to limit the severity of vision loss in some patients with this condition. A number of high-quality international trials have shown that treatment with Lucentis® may not only prevent vision loss, but actually improve vision in those treated."

Dr Sharp identified the impact on the overall health budget of not funding this vision-saving drug. The cost of legal blindness in well documented population studies is estimated at $21,000 per person per year. The cost of treatment of injuries related to falls and the need for residential care more than outweigh the cost of treating macular degeneration.

“Pharmac has suggested that the already over-burdened public hospital clinics should carry the load of treating these patients (and pay for the drug), but treatment with Lucentis® can be given in an ophthalmic doctor’s rooms and doesn’t require attendance at a hospital,” Dr Sharp said.

RANZCO notes that Pharmac did not even ask its ophthalmic specialist subcommittee for an opinion on funding Lucentis. The New Zealand Ophthalmologists are now requesting that Pharmac’s Pharmacology and Therapeutics Advisory Committee formally consult with them so that the evidence can be properly scrutinised.


ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Kakī: World’s Rarest Wading Bird Released In Mackenzie Basin

Conservation Minister Maggie Barry says the birds will add to the 60 released into the Tasman valley earlier this month, significantly boosting the wild population. More>>

ALSO:

IHC Tribute: Colin Meads

"While Colin is best known for rugby, to us he is one of a small number of distinguished IHC New Zealand Life Members recognised for their significant support for people with intellectual disabilities," says IHC Chief Executive Ralph Jones. More>>

ALSO:

Howard Davis Review: Tilting at Turbines - The Trip to Spain

Steve Coogan and Rob Brydon have now both broken the Big Fifty barrier, which seems to have brought a whole new level of angst to their midlife adventures ... More>>

Review: A Rose By Any Other Name Would Smell As Sweet

The Royal New Zealand Ballet has accepted the challenge of this heart-touching tragedy and largely succeeded. More>>

ALSO:

NZ's First Male IAAF Gold: Tom Walsh's Historic Shot Put Victory

Although feeling very sore but with a great feeling Tom Walsh took his place as number one on the victory dais to receive his much deserved gold medal. More>>

ALSO:

Scoop Review Of Books: Q&A: Hard To Find Books

"Unfortunately we are in crisis and this friendly dinosaur faces extinction… Our only hope is to try and raise funds to buy the building and restore it to its glory, either fully funded or with a viable deposit." More>>

 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland